MMV worked with Guilin Pharmaceutical, a Chinese manufacturer, to obtain WHO prequalification for its injectable artesunate in 2010. Twenty-five million vials of injectable artesunate have been delivered since then, saving an estimated additional 165,000 lives compared to treatment with quinine.

Primaquine, the only medicine available to stop malaria relapses, has been in use for 60 years and has a long treatment regimen, which is difficult to adhere to.

MMV is working with GlaxoSmithKline to develop a next-generation anti-relapse medicine that could potentially be taken in a single dose.